Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction

What Was Tested

This observational study paper looks at Tirzepatide and Semaglutide.

Eligibility criteria were then expanded to evaluate treatment effects in patients typically treated in clinical practice.

Why It Was Studied

Heart failure with preserved ejection fraction (HFpEF) is a major cause of hospitalization, often occurring in patients with cardiometabolic comorbidities such as obesity and type 2 diabetes.

New use of semaglutide, tirzepatide, or sitagliptin as a placebo proxy.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Finally, a head-to-head comparison of tirzepatide and semaglutide was implemented.

How the Study Was Run

The researchers set it up as a placebo-controlled study.

The comparison arm used a placebo, so changes seen with Tirzepatide could be set against what happens without it.

The methods mention a period of 52 weeks.

Five cohort studies using national US health care claims data from 2018 to 2024.

Two cohort studies emulated the STEP-HFpEF DM (semaglutide) and SUMMIT (tirzepatide) trials to benchmark results.

Follow-up was up to 52 weeks.

What Was Measured

PubMed files the paper under topics including Cohort Studies, Diabetes Mellitus, Type 2, Heart Failure, Hospitalization, Sitagliptin Phosphate, Stroke Volume and Tirzepatide.

What This Means in Plain Language

The paper is a placebo-controlled study of Tirzepatide and Semaglutide over 52 weeks.

Its findings take up roughly 11 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (JAMA), a journal based in United States.

More context: the Tirzepatide compound page and the Semaglutide compound page, all human trials.